Found: 6
Select item for more details and to access through your institution.
In vitro dendritic cell generation and lymphocyte subsets in myeloma patients: influence of thalidomide and high-dose chemotherapy treatment.
- Published in:
- Cancer Immunology, Immunotherapy, 2005, v. 54, n. 5, p. 506, doi. 10.1007/s00262-004-0633-6
- By:
- Publication type:
- Article
Decreased Soluble Human Leukocyte Antigen E Levels in Patients After Allogeneic Hematopoietic Stem Cell Transplantation Are Associated With Severe Acute and Extended Chronic Graft-versus-Host Disease and Inferior Overall Survival.
- Published in:
- Frontiers in Immunology, 2020, v. 10, p. 1, doi. 10.3389/fimmu.2019.03027
- By:
- Publication type:
- Article
Time series clustering of T cell subsets dissects heterogeneity in immune reconstitution and clinical outcomes among MUD-HCT patients receiving ATG or PTCy.
- Published in:
- Frontiers in Immunology, 2023, v. 14, p. 01, doi. 10.3389/fimmu.2023.1082727
- By:
- Publication type:
- Article
Low Soluble Programmed Cell Death Protein 1 Levels After Allogeneic Stem Cell Transplantation Predict Moderate or Severe Chronic GvHD and Inferior Overall Survival.
- Published in:
- Frontiers in Immunology, 2021, v. 12, p. 1, doi. 10.3389/fimmu.2021.694843
- By:
- Publication type:
- Article
Thalidomide in combination with dexamethasone for pretreated patients with multiple myeloma: serum level of soluble interleukin-2 receptor as a predictive factor for response rate and for survival.
- Published in:
- Annals of Hematology, 2005, v. 84, n. 9, p. 594, doi. 10.1007/s00277-005-1007-7
- By:
- Publication type:
- Article
Combined Analysis of Early CD4 + T Cell Counts and CMV Serostatus May Improve CMV Risk Assessment after Allogeneic Hematopoietic Cell Transplantation.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 12, p. 3318, doi. 10.3390/cells10123318
- By:
- Publication type:
- Article